Evidence map›Paper›PMID 37525239›Full record

ArticleJournal of ovarian research2023

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma.

Paul Jank, Jonas Leichsenring, Svenja Kolb, Inga Hoffmann, Philip Bischoff, Catarina Alisa Kunze, Mihnea P Dragomir, Moritz Gleitsmann, Moritz Jesinghaus, Wolfgang D Schmitt and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Gynecologic oncology reports · 2025
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Paul Jank *Institute of Pathology, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
Jonas Leichsenring *Institute of Pathology, Zytologie Und Molekulare Diagnostik, REGIOMED, Klinikum Coburg, Coburg, Germany.
Svenja KolbDepartment of Gynecology, Vivantes Netzwerk Für Gesundheit GmbH Berlin, Vivantes Hospital Neukölln, Rudower Straße 48, 12351, Berlin, Germany.
Inga HoffmannInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Philip BischoffInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Catarina Alisa KunzeInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Mihnea P DragomirInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Moritz GleitsmannInstitute of Pathology, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
Moritz JesinghausInstitute of Pathology, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
Wolfgang D SchmittInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Hagen KulbeTumorbank Ovarian Cancer Network, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
Christine SersInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Jalid SehouliTumorbank Ovarian Cancer Network, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
Ioana Elena BraicuTumorbank Ovarian Cancer Network, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
Christina WesthoffInstitute of Pathology, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
David HorstInstitute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany.
Carsten DenkertInstitute of Pathology, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
Stefan Gröschel *Oncology Center Worms, Worms, Germany.
Eliane T Taube *Institute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany. eliane.taube@charite.de.

Funding

Berliner Krebsgesellschaft DRFF202204Charité-Universitätsmedizin Berlin and the Berlin Institute of Health BIH-Charité Junior Clinical Scientist ProgramDKTK Berlin Young Investigator Grant 2022Transcan Grant 2014-121
6 · The paper itself

Abstract

backgroundMechanisms of development and progression of high-grade serous ovarian cancer (HGSOC) are poorly understood. EVI1 and PARP1, part of TGF-ß pathway, are upregulated in cancers with DNA repair deficiencies with DNA repair deficiencies and may influce disease progression and survival. Therefore we questioned the prognostic significance of protein expression of EVI1 alone and in combination with PARP1 and analyzed them in a cohort of patients with HGSOC.

methodsFor 562 HGSOC patients, we evaluated EVI1 and PARP1 expression by immunohistochemical staining on tissue microarrays with QuPath digital semi-automatic positive cell detection.

resultsHigh EVI1 expressing (> 30% positive tumor cells) HGSOC were associated with improved progression-free survival (PFS) (HR = 0.66, 95% CI: 0.504-0.852, p = 0.002) and overall survival (OS) (HR = 0.45, 95% CI: 0.352-0.563, p < 0.001), including multivariate analysis. Most interestingly, mutual high expression of both proteins identifies a group with particularly good prognosis. Our findings were proven technically and clinically using bioinformatical data sets for single-cell sequencing, copy number variation and gene as well as protein expression.

conclusionsEVI1 and PARP1 are robust prognostic biomarkers for favorable prognosis in HGSOC and imply further research with respect to their reciprocity.

Indexed as

MDS1 and EVI1 Complex Locus ProteinOvarian NeoplasmsPoly (ADP-Ribose) Polymerase-1Biomarkers, TumorFemaleHumansMiddle AgedPrognosisBiomarkers, TumorMDS1 and EVI1 Complex Locus ProteinMECOM protein, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1BiomarkerEVI1HGSOCOvarian cancerPARPPrognostic biomarker

Identifiers

PMID37525239
PMCPMC10388497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.